The health of your liver can be accurately tracked by looking at the specific types of fat found in your stool.
April 25, 2026
Original Paper
Robiotic Depletion of Gut Enterobacteriaceae Remodels the Fecal Lipidome along the Gut–Liver Axis and Attenuates MASLD: A Randomized Controlled Trial
SSRN · 6626981
The Takeaway
Doctors discovered that certain bad bacteria in the gut directly contribute to liver disease by altering how the body processes fats. In a clinical trial, two specific probiotics were able to clear out these harmful bacteria and significantly improve liver health. This change was reflected in the fecal lipidome, providing a non invasive way to monitor what is happening inside the liver. The study proves that the gut liver axis is a two way street where cleaning up one automatically helps the other. This could lead to a new era of robiotic treatments that manage liver failure through simple dietary changes. Your stool contains a detailed report on your liver metabolic status.
From the abstract
Background: Gut dysbiosis contributes to metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis along the gut–liver axis, yet specific microbial taxa therapeutically targetable in humans remain poorly defined, and robust noninvasive biomarkers for monitoring treatment response are lacking. <br><br>Method: Western diet-fed mice with established MASLD received Pediococcus pentosaceus (PP) or Lactobacillus lactis (LL) as a therapeutic intervention. In a double-blind, randomiz